Evidence map›Paper›PMID 29872540›Full record

ArticleCell discovery2018

Emetine inhibits Zika and Ebola virus infections through two molecular mechanisms: inhibiting viral replication and decreasing viral entry.

Shu Yang, Miao Xu, Emily M Lee, Kirill Gorshkov, Sergey A Shiryaev, Shihua He, Wei Sun, Yu-Shan Cheng, Xin Hu, Anil Mathew Tharappel and 25 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Cell discovery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05889793 (Emetine for Viral Outbreaks), which is not on this map. Cited by 100 papers.

0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed
21.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05889793 phase2 / phase3terminatednot on this mapstarted 2024, after this paper: background citation

Emetine for Viral Outbreaks: Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate Oral Emetine Against Covid-19 (EVOLVE)

TypeinterventionalSponsorJohns Hopkins UniversityRan2024 to 2025Enrolled4ConditionsCOVID-19ArmsEmetine Hydrochloride, Placebo
3 · Its place in the literature

Who cites it

100 citing papers in PubMed, 188 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. [Cephaeline attenuates malignant biological behaviors of colorectal cancer by regulating the Ras signaling pathway].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026
    Article
  6. Review
  7. The Antiviral Activity of Polyphenols.Molecular nutrition & food research · 2025
    Review
  8. Article
  9. Review
  10. An Overview of Zika Virus and Zika Virus Induced Neuropathies.International journal of molecular sciences · 2024
    Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Ocular Manifestations of Flavivirus Infections.Pathogens (Basel, Switzerland) · 2023
    Review
  20. Review

40 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors at 8 institutions in 2 countries.

Shu Yang *1National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Bethesda, MD 20892 USA.
Miao Xu *1National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Bethesda, MD 20892 USA.
Emily M Lee *2Department of Biological Science, Florida State University, Tallahassee, FL 32306 USA.
Kirill Gorshkov1National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Bethesda, MD 20892 USA.ORCID 0000-0002-4652-8818
Sergey A Shiryaev3Development, Aging and Regeneration Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037 USA.
Shihua He4Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2 Canada.
Wei Sun1National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Bethesda, MD 20892 USA.
Yu-Shan Cheng1National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Bethesda, MD 20892 USA.
Xin Hu1National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Bethesda, MD 20892 USA.
Anil Mathew Tharappel2Department of Biological Science, Florida State University, Tallahassee, FL 32306 USA.
Billy Lu1National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Bethesda, MD 20892 USA.
Antonella Pinto3Development, Aging and Regeneration Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037 USA.
Chen Farhy3Development, Aging and Regeneration Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037 USA.
Chun-Teng Huang3Development, Aging and Regeneration Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037 USA.
Zirui Zhang4Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2 Canada.
Wenjun Zhu4Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2 Canada.
Yuying Wu5Department of Biomedical Sciences, Florida State University, Tallahassee, FL 32306 USA.
Yi Zhou5Department of Biomedical Sciences, Florida State University, Tallahassee, FL 32306 USA.
Guang Song6Department of Pharmacology & Molecular Sciences, Johns Hopkins School of Medicine, Baltimore, MD USA.
Heng Zhu6Department of Pharmacology & Molecular Sciences, Johns Hopkins School of Medicine, Baltimore, MD USA.ORCID 0000-0002-8426-2889
Khalida Shamim1National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Bethesda, MD 20892 USA.
Carles Martínez-Romero7Department of Microbiology and Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029 USA.
Adolfo García-Sastre7Department of Microbiology and Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029 USA.
Richard A Preston8Department of Medicine, Miller School of Medicine, University of Miami, Miami, FL 33136 USA.
Dushyantha T Jayaweera8Department of Medicine, Miller School of Medicine, University of Miami, Miami, FL 33136 USA.
Ruili Huang1National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Bethesda, MD 20892 USA.
Wenwei Huang1National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Bethesda, MD 20892 USA.
Menghang Xia1National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Bethesda, MD 20892 USA.
Anton Simeonov1National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Bethesda, MD 20892 USA.
Guoli Ming9Department of Neuroscience and Mahoney Institute for Neurosciences, University of Pennsylvania, Philadelphia, PA 19104 USA.ORCID 0000-0002-2517-6075
Xiangguo Qiu *4Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2 Canada.
Alexey V Terskikh *3Development, Aging and Regeneration Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037 USA.
Hengli Tang *2Department of Biological Science, Florida State University, Tallahassee, FL 32306 USA.
Hongjun Song *9Department of Neuroscience and Mahoney Institute for Neurosciences, University of Pennsylvania, Philadelphia, PA 19104 USA.
Wei Zheng *1National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Bethesda, MD 20892 USA.ORCID 0000-0003-1034-0757
National Institutes of Health · USFlorida State University · USSanford Burnham Prebys Medical Discovery Institute · USPublic Health Agency of Canada · CAIcahn School of Medicine at Mount Sinai · USJohns Hopkins University · USNeurosciences Institute · USUniversity of Miami · US

Funding

Using social networks to map and evaluate team science across CTSA hubsUL1TR001427 · NCATS · UNIVERSITY OF FLORIDA · PI MITCHELL, DUANE A. · 2015 to 2024
$37.2M
Mechanistic Virology CoreU19AI109762 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI SAPHIRE, ERICA OLLMANN · 2014 to 2018
$29.6M
Modeling Zika virus pathogenesis and potential intervention during neural development using a human brain organoid systemU19AI131130 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI BRINTON, MARGO A · 2017 to 2021
$7.7M
Functional roles of genetic risk factors for brain disorders in neurogenesis and neurodevelopmentR35NS097370 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI MING, GUO-LI · 2017 to 2024
$6.7M
Drug Repurposing Screening for Zika Virus InfectionZIATR000269 · NCATS · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · PI ZHENG, WEI · 2016 to 2021
$6.1M
Local circuitry mechanisms regulating adult hippocampal neurogenesisR37NS047344 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI SONG, HONGJUN · 2013 to 2019
$2.9M
Novel Inhibitors of Viral ReplicationR01AI089539 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI FONTOURA, BEATRIZ MA, ROTH, MICHAEL G · 2010 to 2014
$2.0M
Using Chemical Biology to Interfere with the Influenza Virus Life CycleR01AI079110 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI FONTOURA, BEATRIZ MA, ROTH, MICHAEL G · 2010 to 2014
$2.0M
Host-pathogen interactions in ZIKV infection leading to microcephalyR21NS100477 · NINDS · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI SHRESTA, SUJAN, STRONGIN, ALEX Y · 2016 to 2017
$544k
NCATS NIH HHS UL1 TR001427NIAID NIH HHS R01 AI079110NIAID NIH HHS R01 AI089539NIAID NIH HHS U19 AI109762NIAID NIH HHS U19 AI131130NINDS NIH HHS R21 NS100477NINDS NIH HHS R35 NS097370NINDS NIH HHS R37 NS047344
6 · The paper itself

Abstract

The re-emergence of Zika virus (ZIKV) and Ebola virus (EBOV) poses serious and continued threats to the global public health. Effective therapeutics for these maladies is an unmet need. Here, we show that emetine, an anti-protozoal agent, potently inhibits ZIKV and EBOV infection with a low nanomolar half maximal inhibitory concentration (IC

Identifiers

PMID29872540
PMCPMC5986771
OpenAlexW2807500957

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.